TVM Capital Life Science

Founded 1983

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 13
Average round size
info
The average size of a deal this fund participated in
$10M
Portfolio companies 11
Rounds per year 0.34
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.15
Exits 2
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Medical
  • Health Care
  • Pharmaceutical
  • Medical Device
Summary

In 2012 was created TVM Capital Life Science, which is appeared as VC. The venture was found in Europe in Germany. The main department of described VC is located in the Munich.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2015. This TVM Capital Life Science works on 9 percentage points more the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2019. The fund is generally included in less than 2 deals every year. Considering the real fund results, this VC is 42 percentage points more often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the TVM Capital Life Science, startups are often financed by Triathlon Medical Venture Partners, Pearl Street Venture Funds, Pappas Ventures. The meaningful sponsors for the fund in investment in the same round are Triathlon Medical Venture Partners, StandUp Ventures, Signet Healthcare Partners.

We also calculated 3 valuable employees in our database.

Besides, a startup needs to be aged 11-15 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Emovi, Acer Therapeutics, CoLucid Pharmaceuticals. We can highlight the next thriving fund investment areas, such as Clinical Trials, Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of TVM Capital Life Science:
Typical Co-investors
TVM Capital Life Science is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after TVM Capital Life Science:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Germany, Munich
Funds with similar focus located in Germany, Munich:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Vayner Media United States, New York
Boynton Angels United States, Westborough
OPENAIR Equity Partners United States, Kansas City
[email protected] United States, Boston
Tsinghua Holdings China, Beijing
Investment Partners United States, Metuchen
ICICI Bank India, Mumbai
Oddo Meriten Asset Management France, Paris
SMH Venture Finance Limited -
EXOR N.V. The Netherlands, Amsterdam
Palm Tree Crew Investments United States, Miami Beach
Xinjiang Dongfan China, Ürümqi
Shanghai Haoyi China, Shanghai
Ningbo Gaofa Automotive Control System China, Ningbo Shi
Espace-inc Canada, Sherbrooke
Xiamen Qingwa Hechuang Investment China, Xiamen
G100 Capital -
ECO Fund China, Hangzhou
Wuyi Dingfeng Touzi China, Wuyi
[email protected] United States, Boston
Baladi Ventures United States, Israel

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Access Vascular

Advanced Materials
Health Care
Medical Device
Product Management
1
$20M03 Mar 2021 United States, " United States"}

Health Care
Manufacturing
Product Design
1
$15M12 Feb 2021 Canada, Calgary

Vespina Lifesciences

Biopharma
Biotechnology
Life Science
n/a
01 Feb 2021 United States, Newark

Emovi

Medical Device
1
$11M04 Mar 2019 Canada, Montreal

Panthera Dental inc

Dental
Health Care
Manufacturing
Medical
Medical Device
Product Design
n/a
03 Oct 2017 Canada, Quebec City

Acer Therapeutics

Biotechnology
Medical
Pharmaceutical
Therapeutics
n/a
$15M19 Sep 2017 United States, Newton

AL-S Pharma

Health Care
Medical
1
08 Dec 2016 Switzerland, " Switzerland"}

Biotechnology
n/a
$12M05 Dec 2016 United Kingdom, " United Kingdom"}

AurKa Pharma

Biotechnology
Medical
Medical Device
Pharmaceutical
n/a
19 Sep 2016 Canada, Montreal
News
Access Vascular Secures $20M in Series B

– Access Vascular from San Francisco has closed on a Series B round of financing.
TVM Capital Life Science led the round with a $15m commitment, with existing investors also participating.

Access Vascular, Inc. Secures $20 Million in Series B Financing

– A company addressing the most common and costly venous access complications has closed on a Series B round of financing.
TVM Capital Life Science led the round with a $15m commitment, with existing investors also participating.
– The company has developed a proprietary biomaterial platform that is both hydrophilic and lubricious, and has incorporated this material into two commercially-available venous access devices, the HydroPICC® Peripherally Inserted Central Catheter and HydroMID™ Midline Catheter.
– In vitro studies have shown that this biomaterial technology results in an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter.*

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent TVM Capital Life Science?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: